logo
Plus   Neg
Share
Email

Merck's Keytruda Fails Late Stage Clinical Trial

Merck & Co. (MRK) Monday said its cancer treatment Keytruda failed to meet goals in another late-stage study.

Merck said the Phase 3 Keynote-119 trial evaluating Keytruda, Merck's monotherapy for the second- or third-line treatment of patients with metastatic triple-negative breast cancer did not meet its primary endpoint of superior overall survival compared to chemotherapy.

"Metastatic triple-negative breast cancer is an aggressive and challenging disease to treat, especially after progression on initial standard-of-care treatment," said Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

"While we are disappointed by the outcome of this monotherapy trial, we are continuing to study KEYTRUDA in earlier stages of the disease and in combination with chemotherapy to address the unmet medical need of patients with triple negative breast cancer. We are grateful to the patients and investigators for their participation in this important study."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Coffee giant Starbucks Corp. unveiled its sixth and the world's largest Starbucks Reserve Roastery on Chicago's Magnificent Mile, featuring Starbucks Reserve specialty coffee menu, boutique Milanese Princi bakery, and Arriviamo Bar for coffee cocktails. It will throw open the iconic five-storey glass-clad building in 35,000 square feet space, employing about 200 people, to the public on Friday. Retail giant Walmart Inc. reported Thursday a profit for the third quarter that more than doubled from last year, reflecting higher revenues and strength at Walmart U.S. and International. Adjusted earnings per share topped analysts' expectations, while revenues missed it. The company also raised its adjusted earnings outlook for the full-year 2020. German science and technology company Merck KGaA reported Thursday a slight increase in third-quarter profit, despite good growth in sales. The company further lifted its fiscal 2019 earnings and sales view following the closing of the Versum Materials acquisition. Shares of Merck were losing around 2 percent in the morning trading in Germany.
Follow RTT
>